Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman
21.11.2019 21:02:00 EET | Business Wire | Press release
Carbon (www.carbon3d.com), the world’s leading digital manufacturing platform, announced today that Ellen J. Kullman, former Chairman and CEO of DuPont, has been named President and CEO of the company and Dr. Joseph M. DeSimone has been named Executive Chairman of the Board, effective immediately. Kullman will also remain on Carbon’s board of directors where she has served since 2016. Today’s leadership announcements are the result of a succession plan that DeSimone, Kullman, and members of the board have worked on to prepare the company for its next chapter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005835/en/
Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman (Photo: Business Wire)
Carbon has been strengthening its leadership bench over the past several months to support the growth of the business. As President and CEO, Kullman will lead the development and execution of short- and long-term strategies, positioning Carbon to continue delivering value to its employees, customers, partners, and shareholders around the world. DeSimone is transitioning into the role of Executive Chairman to focus on growing mainstream adoption of the Carbon Digital Manufacturing Platform and evangelizing the company’s vision to existing and prospective customers, partners, and the public.
“Today’s announcement is a great honor,” said Kullman. “I am privileged to have spent the last few years on the Carbon board working alongside Joe, one of the greatest entrepreneurs and scientists of our time. Joe has built Carbon into the world’s leading digital manufacturing platform, and as President and CEO of Carbon, I am excited to partner with Joe and build on the solid foundations he’s put into place.”
“For the last six years, I have led Carbon as Chief Executive Officer and am enormously proud of what we’ve accomplished during my tenure,” said DeSimone. “I know what we will accomplish under Ellen will be even more extraordinary. Ellen is the right person to lead Carbon today. She has broad experience across multiple businesses, cycles, and geographies. Her vision, outstanding leadership traits, and distinguished track record will continue to drive Carbon’s growth into the future. In assuming the Executive Chairman role, I will be able to focus on evangelizing the platform and driving adoption more widely.”
Prior to joining DuPont in 1988, Kullman worked for Westinghouse and General Electric. DuPont's board of directors elected Kullman President and a director of the company in October 2008 and Chief Executive Officer in January 2009. She was the nineteenth executive and the first woman to lead the company in its 212-year history. As a business leader, Kullman led double-digit growth of the company’s Safety and Protection business portfolio and started two successful high-growth businesses known today as DuPont Industrial Biosciences and DuPont Sustainable Solutions. During her seven years as CEO, Kullman led the company’s focus on growth in emerging international markets and championed the power of DuPont science and global market knowledge to transform industries. She executed a strong plan and decisively positioned the company for its next generation of growth.
Kullman is co-chair of the Paradigm for Parity coalition and a board director of United Technologies, Dell Technologies, Amgen, and Goldman Sachs. She is a member of the U.S. National Academy of Engineering and past president of the U.S. China Business Council. She serves on the board of trustees of Northwestern University. Kullman has been named one of the “50 Most Powerful Women in Business” by Fortune and one of the “World’s Most Powerful Women” by Forbes. She holds a B.S. in Mechanical Engineering from Tufts University and an MBA from the Kellogg School of Management of Northwestern University.
As co-founder of Carbon, DeSimone took on 3D printing by bringing together insights from diverse fields to co-invent the core technology that now drives the Carbon Platform. Powered by Digital Light Synthesis™ (DLS™) technology, the Carbon Platform is enabling companies to break free of traditional polymer manufacturing methods to advance product innovation. Just this week, he was recognized for his achievements by EY as the U.S. Entrepreneur of the Year.
Before founding Carbon in 2013, DeSimone was a professor at the University of North Carolina for over 20 years. DeSimone has made scientific breakthroughs in areas including green chemistry, medical devices, and nanotechnology, also co-founding several companies based on his research. At UNC, DeSimone built a strong culture in his research group centered on the notion that diversity is a fundamental tenet of innovation.
DeSimone has achieved international recognition as a scientist, inventor, and entrepreneur, earning major accolades including the U.S. Presidential Green Chemistry Challenge Award and the Lemelson-MIT Prize. In 2016, President Obama awarded DeSimone the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. He is also one of only roughly 20 individuals elected to all three U.S. National Academies—the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering.
About Carbon
Carbon’s mission is to reinvent how polymer products are designed, engineered, manufactured, and delivered towards a digital and sustainable future. Based in Silicon Valley, Carbon brings together innovations in software, hardware, and material science to deliver industry-leading digital manufacturing solutions. With Carbon’s ground-breaking Digital Light Synthesis™ technology and broad family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and time to market. To learn more, visit www.Carbon3d.com, like the Carbon Facebook page, or follow Carbon on Instagram and Twitter at @Carbon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005835/en/
Contact information
Iska Hain Saric, Head of Strategic Communications, pr@carbon3d.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
